-transparent.png){kind=logo}
A novel radioiodinated ligand of the butyrophenone type has been synthesized for the quantification and characterization of dopamine D2 receptors. This haloperidol-derived ligand, haloperidol-succinylglycyl[125I]iodotyrosine ([125I]HSGTI), binds rapidly (equilibrium is reached within 30 min, at 10 pM and 37 degrees C) and with high affinity (Kd = 0.3 nM) to bovine striatal membranes. Its pharmacology, determined by competitive displacement with dopaminergic and non-dopaminergic drugs, is characteristic of binding to dopamine D2 receptors.
Related Publications
A M Garrigues, and
F Gehelmann, and
J M Girault, and
M Delaage, and
J Labouesse
November 1984,
Life sciences,
A M Garrigues, and
F Gehelmann, and
J M Girault, and
M Delaage, and
J Labouesse
January 1991,
Psychopharmacology,
A M Garrigues, and
F Gehelmann, and
J M Girault, and
M Delaage, and
J Labouesse
February 1985,
Molecular pharmacology,
A M Garrigues, and
F Gehelmann, and
J M Girault, and
M Delaage, and
J Labouesse
February 2016,
Journal of chemical information and modeling,
A M Garrigues, and
F Gehelmann, and
J M Girault, and
M Delaage, and
J Labouesse
August 1995,
Synapse (New York, N.Y.),
A M Garrigues, and
F Gehelmann, and
J M Girault, and
M Delaage, and
J Labouesse
January 1988,
Progress in neuro-psychopharmacology & biological psychiatry,
A M Garrigues, and
F Gehelmann, and
J M Girault, and
M Delaage, and
J Labouesse
January 1997,
Life sciences,
A M Garrigues, and
F Gehelmann, and
J M Girault, and
M Delaage, and
J Labouesse
April 1991,
Neuroscience letters,
A M Garrigues, and
F Gehelmann, and
J M Girault, and
M Delaage, and
J Labouesse
March 2000,
Psychopharmacology,
A M Garrigues, and
F Gehelmann, and
J M Girault, and
M Delaage, and
J Labouesse
October 1995,
Biochemistry,
